(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Adamas Pharmaceuticals, Inc. | |||||||||||
Dated: | June 11, 2021 | By: | /s/ Christopher B. Prentiss | ||||||||
Christopher B. Prentiss | |||||||||||
Chief Financial Officer |
Cover |
Jun. 09, 2021 |
---|---|
Document Information [Line Items] | |
Document Type | 8-K |
Document Period End Date | Jun. 09, 2021 |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36399 |
Entity Tax Identification Number | 42-1560076 |
Entity Address, Address Line One | 1900 Powell Street |
Entity Address, Address Line Two | Suite 1000 |
Entity Address, City or Town | Emeryville |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94608 |
City Area Code | 510 |
Local Phone Number | 450-3500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | ADMS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001328143 |
Amendment Flag | false |
Entity Registrant Name | ADAMAS PHARMACEUTICALS, INC. |
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end
2J)<3=+L1;&1=['39!$;\+TH:)\$F14)ZP94+JT%_-\VSJS
M<=8#*ZC[LK .YHD46E7D0>DG\0R4SCSI2M4O6BR6E@RB07SLU1D;
M(0R'HX2.DC'2(0*GDRA*: &UL4$L%!@ $ 0
*! $ !(H $!
end
ITI/HQ *3D0$$*(!P$@%0$2:@,"/5&A0
M0(3TVU:"%O'&5A*6D+T*YI^]$K6EV5LA]PKH[0M$&]X/5XHCLWGBDG$,(IT*
MB ,]/2I)FRB#E12'E#=KB\O+NA:9=TK9NVEQ;B\_95?I?3)E@BMIL $A\SG
M 2. T\B...Q40B&J24"Y6V'9B3'28K+"^;-7("UN_@*K:_78);1MQ>A%TS!5
MPHVA#F6AD8/>I6#7\\#R;TQM5_+-INXR_YK.8AGG<7+]NRT=6
;[66R:F#8]'%;C.;V T: ,8
M%K.8V@!IB4\>2* V9LD!*#U$%OK29C\JQM.O?;:>6^:@O2&X.EN6Q?U67W*6
M,85NLR208=S;8PF.44_+$$ F@."&V"%_;;#^-ITVZDZY:9>%_E30/%<;E>
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M!IR RQ(0#)TZ"!T2^"&VO5_;[(>)JO&^FZ92;.*]?^GO3=S=J7JSD5D>N,
M:B*"%:B 0P6